Royalty Pharma Plc (RPRX)

Feb 21, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Bryn Mawr Capital Management LLC - MarketBeat

Feb 21, 2025

Feb 20, 2025

Baillie Gifford & Co. Sells 1,987,975 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 20, 2025

Feb 20, 2025

Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighStill a Buy? - MarketBeat

Feb 20, 2025

Feb 20, 2025

Van ECK Associates Corp Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 20, 2025

Feb 19, 2025

Ex-Dividend Reminder: Royalty Pharma, Piedmont Office Realty Trust and Western Asset Diversified Income - Nasdaq

Feb 19, 2025

Feb 19, 2025

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail

Feb 19, 2025

Feb 19, 2025

(RPRX) Trading Signals - Stock Traders Daily

Feb 19, 2025

Feb 18, 2025

Allspring Global Investments Holdings LLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 18, 2025

Feb 16, 2025

Royalty Pharma (RPRX) to Release Quarterly Earnings on Thursday - MarketBeat

Feb 16, 2025

Feb 15, 2025

Sumitomo Mitsui Trust Group Inc. Reduces Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 15, 2025

Feb 15, 2025

abrdn plc Sells 14,685 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 15, 2025

Feb 15, 2025

Royalty Pharma (NASDAQ:RPRX) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat

Feb 15, 2025

Feb 14, 2025

Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition - MSN

Feb 14, 2025

Feb 13, 2025

Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook - Morningstar

Feb 13, 2025

Feb 13, 2025

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts - MSN

Feb 13, 2025

Feb 13, 2025

Dechert advises Royalty Pharma on lupus drug funding - ICLG.com

Feb 13, 2025

Feb 13, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Lecap Asset Management Ltd. - MarketBeat

Feb 13, 2025

Feb 13, 2025

Royalty Pharma announces R&D funding collaboration with Biogen - TipRanks

Feb 13, 2025

Feb 12, 2025

Royalty Pharma: Delivering Growth With A Positive Story Ahead (NASDAQ:RPRX) - Seeking Alpha

Feb 12, 2025

Feb 12, 2025

Royalty Pharma Earnings: Solid Growth; Diverse Portfolio Supports Positive Long-Term Outlook - Morningstar

Feb 12, 2025

Feb 12, 2025

Royalty Pharma plc (RPRX) reports earnings - Quartz

Feb 12, 2025

Feb 12, 2025

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma - Benzinga

Feb 12, 2025

Feb 12, 2025

Royalty Pharma plc SEC 10-K Report - TradingView

Feb 12, 2025

Feb 12, 2025

Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D -February 12, 2025 at 08:32 am EST - Marketscreener.com

Feb 12, 2025

Feb 12, 2025

Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 12, 2025

Feb 12, 2025

Royalty Pharma plc (RPRX): A Cheap Biotech Stock to Invest In Now - Yahoo Finance

Feb 12, 2025

Feb 12, 2025

Royalty Pharma plc (RPRX) Announces R&D Funding Collaboration With Biogen - StreetInsider.com

Feb 12, 2025

Feb 12, 2025

Massive $250M Deal: Royalty Pharma Backs Revolutionary Lupus Treatment in Late-Stage Trials - StockTitan

Feb 12, 2025

Feb 12, 2025

Royalty Pharma’s Optimistic Earnings Call Highlights Growth - TipRanks

Feb 12, 2025

Feb 12, 2025

Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... By GuruFocus - Investing.com Canada

Feb 12, 2025

Feb 12, 2025

10 Cheap Biotech Stocks to Invest in Now - Insider Monkey

Feb 12, 2025

Feb 11, 2025

Royalty Pharma PLC Reports Strong 2024 Financial Results - TipRanks

Feb 11, 2025

Feb 11, 2025

Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings - MSN

Feb 11, 2025

Feb 11, 2025

Earnings call transcript: Royalty Pharma Q4 2024 misses EPS forecast By Investing.com - Investing.com Canada

Feb 11, 2025

Feb 11, 2025

Earnings call transcript: Royalty Pharma Q4 2024 misses EPS forecast - Investing.com India

Feb 11, 2025

Feb 11, 2025

Royalty Pharma earnings missed by $0.63, revenue fell short of estimates - Investing.com South Africa

Feb 11, 2025

Feb 11, 2025

Royalty Pharma (RPRX) Reports Q4 Revenue of $594 million - StreetInsider.com

Feb 11, 2025

Feb 11, 2025

Royalty Pharma reports Q4 portfolio receipts of $742M - TipRanks

Feb 11, 2025

Feb 11, 2025

Royalty Pharma Q4 Net Income, Revenue Decrease -February 11, 2025 at 07:41 am EST - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

Royalty Pharma Reports Q4 and Full Year 2024 Results - TradingView

Feb 11, 2025

Feb 11, 2025

Royalty Pharma: Q4 Earnings Snapshot -February 11, 2025 at 07:31 am EST - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

Earnings Flash (RPRX) Royalty Pharma Reports Q4 Revenue $594M, vs. FactSet Est of $687.1M - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

Royalty Pharma Reports Strong Q4 and FY 2024 Financial Results with Expectations for Continued Growth in 2025 - Nasdaq

Feb 11, 2025

Feb 11, 2025

Royalty Pharma's Triple Win: 12% Revenue Jump, Massive Buyback, and Strategic Acquisition - StockTitan

Feb 11, 2025

Feb 10, 2025

Royalty Pharma Earnings: What To Look For From RPRX - Barchart

Feb 10, 2025